NY-ALTER-DOMUS
23.1.2024 10:01:32 CET | Business Wire | Press release
Alter Domus, a leading provider of tech-enabled fund administration, private debt, and corporate services for the alternative investment industry, today unveiled the creation of its Key Client Partnerships (KCP) practice to help private markets firms scale their middle- and back-office infrastructure to meet increasing investor demands and mounting complexity. This creation comes as a natural consequence of the firm’s 20-year track record of building long-lasting relationships with major private markets firms.
As the pace of growth in the private markets continues to increase, so too has technology, regulatory and investor reporting requirements. In response, Alter Domus’ KCP practice aims to meet private markets firms’ need for dedicated support on defining and implementing new target operating models to support their future growth and scalability.
The Key Client Partnerships approach is centered on investing in long-term relationships with clients that covers everything from migrating products from one platform to another, to handling all outsourcing and technology interfacing, to managing all the governance and risk mitigation aspects of team and technology transitions.
Depending on their strategic priorities, joint operating models are built on one of three broad operational foundations:
- Co-sourced: Alter Domus’ expert administration team continues to use a client’s technology, processes and data infrastructure. The benefits of this model include Alter Domus managing HR responsibilities for the client’s team, no disruptions from the client’s current model, and retention of any bespoke technology platform developments.
- Managed service: An expert team actively manages a client’s technology and processes, while the client controls its data infrastructure. The advantages of this model include access to Alter Domus’ deep administration, technology and process expertise, its absorption of technology costs, and retention of bespoke data interfaces and developments on behalf of the client, as well as Alter Domus’ ongoing investments in technology platform upgrading and innovation.
- Out-sourced: Alter Domus experts handle every aspect of a client’s administration needs, including technology and data infrastructure. Information is delivered through Alter Domus’ client portal, CorPro, or direct API connectivity. Alter Domus absorbs data and infrastructure costs and provides the client with full access to its industry-leading platforms, servicing and technology developments and innovation.
In addition, Alter Domus’ KCP team will support its clients in building the relevant financial model for the partnership, and lead the transition to the target operating model.
Alter Domus head of Key Client Partnerships Steve Krieger, said: “The focus of clients is investment management – raising money, deploying capital, managing risks – not fund servicing, accounting and compliance. Our new practice responds to private markets managers’ growing requirement for hands-on support on how to renew entire operating models that are no longer fit for purpose. Supported by our decades of administration expertise and industry-leading technology, fund managers can now partner with a dedicated team of Alter Domus experts to ‘co-create’ global operating models customized to their specific priorities.”
About Alter Domus
Alter Domus is a leading provider of tech-enabled fund administration, private debt, and corporate services for the alternative investment industry with more than 5,100 employees across 39 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services.
Find out more at www.alterDomus.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123600245/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
